Adimab (https://www.adimab.com/) is the leading technology provider for therapeutic antibody drug discovery, focusing solely on our partnerships without pursuing an internal product pipeline. Since 2009, we have partnered (https://www.adimab.com/partnering) with over 130 pharmaceutical and biotechnology companies, generating more than 575 therapeutic programs, of which more than 75 have entered clinical trials.   

Role Overview: 

Adimab seeks a graduate student intern to contribute to projects aimed at generating de novo antibody designs for experimental testing in our platform. 

Requirements:

• Experience in antibody: antigen structure prediction, computational binder design, or in silico methods for distinguishing native protein: protein interfaces, demonstrated through thesis work, presentations, preprints, or publications. 

• Hands-on experience with AlphaFold, ProteinMPNN, and similar tools; proficient in Python, Tensorflow, and PyTorch. 

• The ideal candidate has passed their PhD qualifiers and is 3-4 years into the program. 

   

  Responsibilities 

• Generate de novo antibody designs using applicable computational methods. 

• Work with experimental groups to test predictions and use their feedback to refine the design process. 

  Location, timing, and compensation 

• Fully on-site with our Computational Biology group located in Mountain View, California.  

• Start date in Spring/Summer 2025 for approximately 12-16 weeks. 

• Competitive compensation and relocation assistance (if applicable). 

  Come join us! 

  Our integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs with exquisite specificity and biophysical behavior. We offer fundamental advantages by delivering diverse panels of antibodies that meet the most demanding standards for affinity, epitope specificity, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of arrangements for technology access. 

  As a profitable privately held biotech company, we take a long-term view on value creation and make substantial investments in technology development, research, and our people. 

Powered by JazzHR